JANX Insider Trading Activity and SEC Form 4 Filings
JANX insider trading summary
Over the past 12 months, insiders at Janux Therapeutics, Inc. (JANX) reported 10 sales worth $500K by 6 insiders and no open-market purchases on SEC Form 4. Net insider selling was $500K.
Latest JANX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 11, 2026 | Maria Dobek | Vice President, Accounting | Sell | $29K (2,038 @ $14.17) |
| Jan 2, 2026 | Maria Dobek | Vice President, Accounting | Sell | $20K (1,462 @ $13.73) |
| Jan 2, 2026 | David Alan Campbell | President and CEO | Sell | $111K (8,072 @ $13.73) |
| Jan 2, 2026 | Zachariah McIver | Chief Medical Officer | Sell | $37K (2,714 @ $13.73) |
| Jan 2, 2026 | Charles M. Winter | Chief Technical Officer | Sell | $33K (2,401 @ $13.73) |
| Jan 2, 2026 | Thomas DiRaimondo | Chief Scientific Officer | Sell | $34K (2,505 @ $13.73) |
| Jan 2, 2026 | Andrew Hollman Meyer | Chief Business Officer | Sell | $26K (1,879 @ $13.73) |
| Dec 1, 2025 | Andrew Hollman Meyer | Chief Business Officer | Sell | $89K (2,700 @ $32.85) |
| Dec 1, 2025 | Andrew Hollman Meyer | Chief Business Officer | Sell | $21K (633 @ $33.52) |
| Nov 14, 2025 | Andrew Hollman Meyer | Chief Business Officer | Sell | $100K (3,333 @ $30.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.